

For practical information concerning this Roche satellite symposium, contact Nadia Boulafdal (Tel: 02/525.82.94 or nadia.boulafdal@roche.com)

For more information on IMPAKT Breast Cancer Conference (2-4 May, 2013): www.impakt.org

IMPAKT 2013 Industry Satellite Symposium

SQUARE
BRUSSELS MEETING CENTRE

Mont des Arts-Kunstberg
1000 Brussels



- 1 GLASS ENTRANCE
MONT DES ARTS - KUNSTBERG
- 2 TERRACE ENTRANCE
MONT DES ARTS - KUNSTBERG
- 3 RAVENSTEIN ENTRANCE
2 RUE RAVENSTEINSTRAT
- 4 COUDENBERG ENTRANCE
3 COUDENBERG
- 5 PARKING ALBERTINE
DIRECT ACCESS TO SQUARE



**Latest clinical advances and biomarker research in
HER2-positive breast cancer**

Chaired by Martine Piccart, MD, PhD



**Thursday, May 2nd, 2013
12:00 - 13:00**

*Silver Hall, SQUARE Brussels meeting center
Lunch will be provided as from 11:30*

Dear colleagues,

It is my pleasure to invite you to the symposium 'Latest clinical advances and biomarker research in HER2-positive breast cancer' sponsored by Roche. This scientific meeting will take place during the IMPAKT Breast Cancer Conference on Thursday, May 2nd, 2013 from 12:00 to 13:00 in the Silver Hall of the SQUARE Brussels meeting center.

On this occasion, I have invited international experts to join me to discuss the latest clinical developments and latest biomarker research in HER2-positive breast cancer. We will close the symposium with an interactive round table discussion on questions that still remain open in this challenging disease area.

These are exciting times for the treatment of HER2-positive breast cancer, and I am looking forward to seeing you on May 2nd for a stimulating and informative meeting.

Yours sincerely,



Martine Piccart, MD, PhD
Institut Jules Bordet, Belgium

Latest clinical advances and biomarker research in HER2-positive breast cancer

Thursday, May 2nd, 2013 12:00 - 13:00

Silver Hall, SQUARE Brussels meeting center

PROGRAM

Chaired by Martine Piccart, MD, PhD

The next wave of successful drug therapy strategies in HER2-positive breast cancer (20')

Hans Wildiers, MD, PhD
UZ Leuven, Belgium

Is there a place for other biomarkers beyond HER2 in HER2-positive breast cancer? (20')

Astrid Kiermaier, PhD
Personalized Health Care Leader, Roche, Switzerland

Roundtable discussion (20')

With Fabrice André, MD, PhD (FR), Luc Dirix, MD, PhD (BE), Sherene Loi, MD, PhD (AU), Gordon B. Mills, MD, PhD (USA), Jorge S. Reis-Filho, MD, PhD (USA).

Lunch will be provided as from 11:30 at the Silver Hall entrance for the satellite symposium attendees.